Key Event Details
The United States Food and Drug Administration (US FDA) conducted an unannounced inspection of Rubicon Research Limited's manufacturing facility located at Plot No. A-17, Special Economic Zone, Phase-II, Industrial Area, Pithampur, District Dhar, PIN – 454 775, Madhya Pradesh. The inspection period was from Monday, 29 June 2026 to Friday, 3 July 2026.
Facility Background
This was the first US FDA inspection of this facility since its acquisition by the company last year. The company completed integration of the facility, implemented quality management systems, and completed regulatory filings that initiated the inspection requirement within the 12 months since acquisition.
Inspection Outcome
Upon conclusion of the inspection, the US FDA issued a Form 483 containing 2 observations. The observations are characterized as procedural in nature and do not relate to data integrity.
Company Response and Outlook
The company expressed confidence in working closely with the regulator to successfully conclude the evaluation in a timely manner. The disclosure states that a successful inspection outcome would reflect the company's quality & compliance culture and reinforce its strong regulatory track record.
As guided in the Q4 FY2026 investor update, the company remains confident of ramping up commercial operations at this facility from Q1 of calendar year 2027.
The company committed to keeping stock exchanges informed of any further updates on this subject.